HC Wainwright Reiterates Buy Rating for Astria Therapeutics (NASDAQ:ATXS)
Astria Therapeutics (NASDAQ:ATXS – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $16.00 price target on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 124.09% from the stock’s current […]
Astria Therapeutics (NASDAQ:ATXS – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $16.00 price target on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 124.09% from the stock’s current […]
